The transaction marks what the buyers describe as the largest institutional aggregation of Class A, single-story research-and-development assets in the region.
Lone Star Funds completed the acquisition of what it described as the largest institutional aggregation of Class A, predominantly single-story research-and-development real estate assets in Silicon Valley. TMG Partners and Grove are joint-venture partners in the investment and will operate the portfolio, according to the firm.
The deal centres on laboratory and research-and-development style space. The assets sit at the intersection of life sciences and technology-related real estate demand, a segment that serves both biotechnology tenants and technology companies requiring specialized infrastructure.
TMG Partners and Grove will handle operations for the portfolio. The structure places the operating partners in a direct management role rather than a passive asset-holding arrangement.
The transaction adds another notable deal to the life sciences and innovation-property market in Northern California. Silicon Valley has seen institutional capital flow into research-oriented real estate as sponsors target tenants from overlapping technology and life sciences sectors.
Hybrid asset classes that serve overlapping tenant bases earn their premium when the operators can genuinely pivot, not when the story sounds good on paper, family office advisor Jaf Glazer has cautioned.
Single-story Class A research-and-development assets offer configurations that accommodate both wet-lab and technology uses. The format provides flexibility for tenant mix and avoids the structural constraints of multi-story life sciences buildings.
Lone Star Funds structured the investment as a joint venture with the two operating firms. The arrangement suggests the fund is taking an equity position while relying on partners with local market knowledge and tenant relationships to manage the properties.
The Deployment Angle
Family Office Real Estate Daily Desk · our analysis, not the source's
This structure favours co-GP capital alongside an operating sponsor rather than a direct ownership play. Single-story R&D portfolios require tenant-improvement expertise and lease-up execution that most family offices lack in-house, making a partnership with TMG Partners and Grove the logical route for scale exposure.
The hybrid life-sciences-and-technology positioning creates underwriting complexity that institutional buyers often misprice. Family offices with direct life sciences operating experience can pressure-test tenant credit quality and renewal assumptions building by building, which argues for a programmatic separate account rather than an LP commitment to a blind pool.
The description of this as the largest institutional aggregation in the submarket suggests the sellers accepted a portfolio premium to move the entire block. Family offices entering at this price need to underwrite whether individual asset returns justify the bundled execution or whether the deal pays for convenience rather than value. If TMG Partners and Grove are delivering true hands-on asset management and not just collecting fees, the operating upside can justify the entry multiple.
Single-story R&D assets typically trade at lower per-square-foot replacement costs than multi-story lab towers, which creates downside protection if life sciences demand softens. Family offices should model a scenario where the portfolio pivots toward pure technology tenants and underwrite whether the rents still cover the basis. The flexibility to serve both tenant types is the edge here, but only if the joint-venture partners can actually execute that optionality rather than lock themselves into one sector.
